<a href="https://laohu8.com/S/LFST">LifeStance Health</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> Revenue Growth of 11% to $345.<a href="https://laohu8.com/S/MMM">3M</a>, Net Loss Narrows to $3.8M, Adjusted EBITDA Rises 19% to $34M
LifeStance Health Group Inc. reported a net loss of $3.8 million, a significant improvement from the net loss of $23.3 million in the previous period. In the second quarter, the company achieved net cash provided by operations amounting to $64.4 million and a free cash flow of positive $56.6 million. Adjusted EBITDA increased by 19%, reaching $34.0 million, compared to $28.6 million previously. For the full year 2025, LifeStance reiterated its revenue expectations of $1.40 billion to $1.44 billion. The company raised its Center Margin expectations to $441 million to $465 million and increased its Adjusted EBITDA expectations to a range of $140 million to $150 million. CEO Dave Bourdon highlighted the addition of over 170 clinicians and improved productivity, contributing to double-digit organic revenue growth and 10% Adjusted EBITDA margins.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeStance Health Group Inc. published the original content used to generate this news brief on August 07, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。